e-Therapeutics plc Patent Filing Applications (5745O)
11 Octubre 2021 - 1:05AM
UK Regulatory
TIDMETX
RNS Number : 5745O
e-Therapeutics plc
11 October 2021
e-therapeutics plc
("e-therapeutics" or the "Company")
Patent Filing Applications
Further advancement in the Company's RNAi Platform
Development
Oxford, UK, 11 October 2021 - e-therapeutics plc (AIM: ETX;
OTCQX; ETXPF), a specialist in computational drug discovery with a
focus on developing RNA interference ("RNAi") therapeutics, is
pleased to announce new patent filings to protect the Company's
proprietary RNAi platform technology for liver gene silencing.
The Company has recently filed five new patent applications
relating to its innovative GalNAc-conjugated siRNA (short
interfering RNA) construct designs, including around stabilising
chemical modifications enabling specific hepatocyte (liver cell)
targeting.
Ali Mortazavi, Chief Executive Officer of e-therapeutics,
commented: "Since our capital raise in May, we have made excellent
progress in all areas of the Company. We expect to present data
from our RNAi platform in our Interim Results announcement on
Tuesday 26 October, when the in vivo characterisation studies will
have been completed."
Enquiries :
e-therapeutics plc Tel: +44 (0)1993 883
125
Ali Mortazavi, CEO www.etherapeutics.co.uk
Karl Keegan, CFO
Laura Roca-Alonso, CBO
SP Angel Corporate Finance LLP Tel: +44(0)20 3470
0470
Nominated Adviser and Broker
Matthew Johnson/Caroline Rowe (Corporate
Finance)
Vadim Alexandre/Rob Rees (Corporate
Broking)
About e-therapeutics plc
e-therapeutics plc is an Oxford, UK-based company integrating
computational power and biology to accelerate the discovery of
life-transforming medicines. The Company has developed and
validated a powerful, disease and modality agnostic computational
approach to drug discovery, leveraging its industry-leading
expertise in network biology to fully capture and interrogate human
disease complexity.
The Company's multi-disciplinary team builds computational
models of biological functions to transform the search for new
medicines, interventions, mechanisms and genetic support. Its
biology-led in silico laboratory enables rapid hypothesis
generation and phenotypic screening of millions of compounds
leading to 100-1,000x higher hit rates in the wet lab and
successful mode of action elucidation. Novel targets can also be
identified, prioritised and assessed. Harnessing internal target
gene discoveries, e-therapeutics is currently building an in-house
pipeline of RNAi based medicines, using its proprietary
GalNAc-siRNA technology.
e-therapeutics has deployed and validated its disease-agnostic
computational drug discovery platform both in house and with
partners, including Novo Nordisk, Galapagos NV and a US-based, top
five pharmaceutical company.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCFLFFLIVLAIIL
(END) Dow Jones Newswires
October 11, 2021 02:05 ET (06:05 GMT)
E-therapeutics (LSE:ETX)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
E-therapeutics (LSE:ETX)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024